Back to top
more

Tango Therapeutics (TNGX)

(Delayed Data from NSDQ)

$7.44 USD

7.44
301,906

+0.11 (1.50%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $7.43 -0.01 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (75 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -14.29% and 30.90%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

MeiraGTx Holdings PLC (MGTX) Reports Q4 Loss, Misses Revenue Estimates

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -2.17% and 79.86%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Ekta Bagri headshot

3 Cancer-Focused Biotechs That Appear Promising Bets for 2024

With the spotlight on oncology-focused companies in the biotech sector in 2023, we discuss three stocks that have a promising oncology portfolio/pipeline for 2024.

Wall Street Analysts Predict an 110.53% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 110.5% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Tango Therapeutics, Inc. (TNGX)? Wall Street Analysts Think 115.31%

The consensus price target hints at an 115.3% upside potential for Tango Therapeutics, Inc. (TNGX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

IDEAYA Biosciences, Inc. (IDYA) Surges 7.6%: Is This an Indication of Further Gains?

IDEAYA Biosciences, Inc. (IDYA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Tango Therapeutics (TNGX) Rises 20% in a Month: Here's Why

The upside in Tango's (TNGX) shares can be attributed to the company's progress with its pipeline candidates. A recent acquisition offer for a biotech making similar drugs also bolstered this surge.

What Makes Tango Therapeutics, Inc. (TNGX) a Good Fit for 'Trend Investing'

Tango Therapeutics, Inc. (TNGX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Tango Therapeutics, Inc. (TNGX) Reports Q2 Loss, Tops Revenue Estimates

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 34.29% and 108.54%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Repligen (RGEN) Q2 Earnings Surpass Estimates

Repligen (RGEN) delivered earnings and revenue surprises of 8.16% and 4.77%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Acadia (ACAD) Soars 24.7%: Is Further Upside Left in the Stock?

Acadia (ACAD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Tango Therapeutics, Inc. (TNGX) Reports Q1 Loss, Misses Revenue Estimates

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 11.11% and 13.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Qiagen (QGEN) Q1 Earnings Beat Estimates

Qiagen (QGEN) delivered earnings and revenue surprises of 8.51% and 0.09%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Tango Therapeutics, Inc. (TNGX) Reports Q4 Loss, Lags Revenue Estimates

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of 8.33% and 2.86%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?

Mirati (MRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Tango Therapeutics, Inc. (TNGX) Reports Q3 Loss, Tops Revenue Estimates

Tango Therapeutics, Inc. (TNGX) delivered earnings and revenue surprises of -3.13% and 15.99%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Cara Therapeutics (CARA) Reports Q3 Loss, Tops Revenue Estimates

Cara (CARA) delivered earnings and revenue surprises of -2.38% and 28.91%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Denali Therapeutics Inc. (DNLI) Reports Q3 Loss, Lags Revenue Estimates

Denali Therapeutics Inc. (DNLI) delivered earnings and revenue surprises of -1.20% and 64.61%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Tango Therapeutics, Inc. (TNGX) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release

Tango Therapeutics, Inc. (TNGX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tango Therapeutics, Inc. (TNGX) Stock Jumps 16.3%: Will It Continue to Soar?

Tango Therapeutics, Inc. (TNGX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Can Tango Therapeutics, Inc. (TNGX) Climb 219% to Reach the Level Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 219.4% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 176% Upside in Tango Therapeutics, Inc. (TNGX): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 176.2% in Tango Therapeutics, Inc. (TNGX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.